Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 819 |
| Number of pages | 1 |
| Journal | Blood |
| Volume | 124 |
| Issue number | 21 |
| Publication status | Published - 2014 |
Cite this
}
A thrombopoietin antagonist is capable of affecting stem and progenitor cells of patients with myelofibrosis. / Wang, Xiaolin; Haylock, David; Hu, Cing Siang; Mosoyan, Goar; Winkler, D.A.; Hoffman, Ronald.
In: Blood, Vol. 124, No. 21, 2014, p. 819.Research output: Contribution to journal › Article › Other
TY - JOUR
T1 - A thrombopoietin antagonist is capable of affecting stem and progenitor cells of patients with myelofibrosis
AU - Wang, Xiaolin
AU - Haylock, David
AU - Hu, Cing Siang
AU - Mosoyan, Goar
AU - Winkler, D.A.
AU - Hoffman, Ronald
PY - 2014
Y1 - 2014
N2 - Aberrant thrombopoietin (TPO)/MPL signaling has been hypothesized to contribute to the pathogenesis of myelofibrosis (MF). Agents that would be capable of inhibiting this signaling pathway are possible novel therapeutic agents that might be effective for MF treatment. A peptide antagonist of TPO, LCP4, has been created which is highly antagonistic to CB CD34+ cell proliferation and differentiation induced by TPO. In this report we examined the effect of LCP4 on the proliferation of MF CD34+ cells and their differentiation to megakaryocytes (Mk).
AB - Aberrant thrombopoietin (TPO)/MPL signaling has been hypothesized to contribute to the pathogenesis of myelofibrosis (MF). Agents that would be capable of inhibiting this signaling pathway are possible novel therapeutic agents that might be effective for MF treatment. A peptide antagonist of TPO, LCP4, has been created which is highly antagonistic to CB CD34+ cell proliferation and differentiation induced by TPO. In this report we examined the effect of LCP4 on the proliferation of MF CD34+ cells and their differentiation to megakaryocytes (Mk).
UR - http://www.bloodjournal.org/content/124/21/819
M3 - Article
VL - 124
SP - 819
JO - Blood
JF - Blood
SN - 0006-4971
IS - 21
ER -